Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology. | Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Tempus to acquire cancer test maker Personalis for $1.5B
Tempus AI strikes $1.5B deal for Personalis, betting big on AI-powered cancer detection
Tempus AI Scoops Up Genomics Play For $1.5 Billion; But Shares Dive
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition - Personalis (NASDAQ:PSNL), Tempu
Why Is Tempus AI Stock Volatile Tuesday? - Personalis (NASDAQ:PSNL), Tempus AI (NASDAQ:TEM)
Merck Reportedly Goes To Bat In Takeover Battle
Massive Bio Partners With FOMAT to Expand Cancer Patient Prescreening for Clinical Trial Access
Kelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 program
GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal
Fierce Pharma Asia—GSK, Merck ADCs’ trial wins; AZ’s $1.5B EGFR buy; Biotechs’ new patent tricks
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Tempus AI acquires Personalis for $1.5 billion to expand cancer MRD testing capabilities, targeting a $20 billion market with…
Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies…
Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD market.
Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.
Personalis stock popped Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company.
